Radioimmunotherapy of lymphoma: A treatment approach ahead of its time or past its sell-by date?

Journal of Clinical Oncology

Volumn 28, Issue 18, 2010, Pages 2944-2946

  Illidge, Tim Martin ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IBRITUMOMAB TIUXETAN; RITUXIMAB; TOSITUMOMAB I 131;

FOLLOW UP; HUMAN; NONHODGKIN LYMPHOMA; NOTE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TREATMENT FAILURE; TREATMENT RESPONSE; ARTICLE; IMMUNOLOGY; LYMPHOMA; TIME;

HUMANS; LYMPHOMA; RADIOIMMUNOTHERAPY; TIME FACTORS;

EID: 77954619428     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.8748     Document Type: Note

References (28)

1. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 (Pubitemid 34438862)
2. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005 (Pubitemid 40223656)
3. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005 (Pubitemid 41742196)
4. Schulz H, Bohlius JF, Trelle S, et al: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. J Natl Cancer Inst 99:706-714, 2007 (Pubitemid 47078732)
5. Park SI, Press OW: Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. Curr Opin Hematol 14:632-638, 2007 (Pubitemid 47494079)
6. Kaminski MS, Zelenetz AD, Press OW, et al: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19:3918-3928, 2001 (Pubitemid 32912019)
7. Fisher RI, Kaminski MS, Wahl RL, et al: Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 23:7565-7573, 2005 (Pubitemid 46291820)
8. Horning SJ, Younes A, Jain V, et al: Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 23:712-719, 2005 (Pubitemid 46224170)
9. Witzig TE, Flinn IW, Gordon LI, et al: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262-3269, 2002 (Pubitemid 34831524)
10. Gordon LI, Molina A, Witzig T, et al: Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study. Blood 103:4429-4431, 2004 (Pubitemid 38745967)
11. Kaminski MS, Tuck M, Estes J, et al: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441-449, 2005 (Pubitemid 40175970)
12. Leonard JP, Coleman M, Kostakoglu L, et al: Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol 23:5696-5704, 2005
13. Link B, Kaminski MS, Coleman M, et al: Phase II study of CVP followed by tositumomab and iodine I-131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma. J Clin Oncol 22:562s, 2004 (suppl; abstr 6520)
14. Press OW, Unger JM, Braziel RM, et al: Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24:4143-4149, 2006 (Pubitemid 46622291)
15. Morschhauser F, Radford J, Van Hoof A, et al: Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156-5164, 2008
16. Illidge TM, Bayne M, Brown NS, et al: Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: The effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 113:1412-1421, 2009
17. Shipley DL, Greco FA, Spigel DR, et al: Rituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: Update of a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 23:579s, 2005 (suppl; abstr 6577)
18. Jacobs SA, Swerdlow SH, Kant J, et al: Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 14:7088-7094, 2008
19. Morschhauser F, Illidge T, Huglo D, et al: Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 110:54-58, 2007 (Pubitemid 47026818)
20. Liu SY, Eary JF, Petersdorf SH, et al: Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 16:3270-3278, 1998 (Pubitemid 28481621)
21. Vose JM, Bierman PJ, Enke C, et al: Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 23:461-467, 2005 (Pubitemid 46224222)
22. Gisselbrecht C, Decaudin D, Mounier N, et al: Yttrium-90 ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory follicular lymphoma: GELA phase II study. Blood 110:14a, 2007 (abstr 22)
23. Krishnan A, Nademanee A, Fung HC, et al: Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 26:90-95, 2008
24. Winter JN, Inwards DJ, Spies S, et al: Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 27:1653-1659, 2009
25. Witzig TE, White CA, Gordon LI, et al: Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 21:1263-1270, 2003 (Pubitemid 46606402)
26. Bennett JM, Kaminski MS, Leonard JP, et al: Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 105:4576-4582, 2005 (Pubitemid 40807274)
27. Czuczman MS, Emmanouilides C, Darif M, et al: Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 25:4285-4292, 2007 (Pubitemid 47548569)
28. Provencio M, Sanchez A, Maximiano C, et al: A prospective study of left ventricle function after treatment with rapid-infusion rituximab in patients with non-Hodgkin lymphoma. Leuk Lymphoma 50:1642-1646, 2009